Dr Mariska Leeflang
Dept. Clinical Epidemiology, Biostatistics and
Bioinformatics
Academic Medical Center, University of Amsterdam
Room J1B - 210
PO Box 227700
1100 DE Amsterdam
m.m.leeflang@amc.uva.nl

Quality assessment of diagnostic test accuracy studies

Montreal, Monday May 25th, 2009

Mariska Leeflang

Steps in a systematic review

- Formulating the question


 (and defining criteria for inclusion of studies)
- Searching for studies
- 3. Selecting studies
- 4. Collecting data
- 5. Assessing methodological quality
- Analysing and presenting results
- 7. Interpreting results

Quality assessment


Why assess quality?

- Problem 1: Bias in primary studies can lead to misleading summary estimates of accuracy
- Problem 2: Results of primary studies may vary
- Quality assessment to guide the interpretation of results in terms of potential for bias and sources of heterogeneity


Echocardiography in Coronary Heart Disease




GLAL in Gram Negative Sepsis



F/T PSA in the Detection of Prostate cancer



Dip-stick Testing for Urinary Tract Infection



Cochrane definition of quality

"the methodological quality of a study; the degree to which the design and conduct of a study fit to the study objectives"

How to assess quality?

- Quality assessment tools:
 - Large number of different tools
 - Styles: Quality scores/levels of evidence/ component approach
 - Cochrane handbook recommends modified version of the QUADAS tool

QUADAS

- General tool
- Systematically developed based on empirical evidence and a formal consensus method
- Set of 11 required (strongly suggested) items, and a list of additional items to consider

QUADAS items

| 1 | Was the spectrum of patients representative of the patients who will receive the test in practice? | | |
|----|---|--|--|
| 2 | Is the reference standard likely to correctly classify the target condition? | | |
| 3 | Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests? | | |
| 4 | Did the whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis? | | |
| 5 | Did patients receive the same reference standard regardless of the index test result? | | |
| 6 | Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard)? | | |
| 7 | Were the index test results interpreted without knowledge of the results of the reference standard? | | |
| 8 | Were the reference standard results interpreted without knowledge of the results of the index test? | | |
| 9 | Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? | | |
| 10 | Were uninterpretable/ intermediate test results reported? | | |
| 11 | Were withdrawals from the study explained? | | |

Sources of bias and variation

Whiting P et al. Ann Intern Med. 2004; 140(3): 189-202.


overview of sources of bias and variation

Whiting P et al. BMC Med Res Methodol. 2003; 3:25.

development of QUADAS

Cochrane Handbook for Reviews of Diagnostic Test Accuracy

Basic Test Accuracy Study




Problems with spectrum


Measures of accuracy vary across patient groups:

- o Patient characteristics e.g. age
- Patient selection/Study design
- Setting


Diagnostic case-control design




Reference standard bias




Time between index test and reference standard




Partial verification bias




Differential verification bias




Incorporation bias



Blinding



Blinding



Two important reporting items

- Reporting of uninterpretable/ intermediate test results
- Explanation of withdrawals

| | biopsy | | |
|------|--------|-----|-----|
| _ | + | ı | |
| HPV+ | 45 | 68 | 113 |
| +/- | 20 | 25 | 45 |
| HPV- | 7 | 161 | 198 |
| | 72 | 254 | 356 |

Lower estimate | Higher estimate of diagnostic accuracy of diagnostic accuracy Study characteristics* RDOR (95% CI) Severe cases and healthy controls 4.9 (0.6-37.3) Other case-control designs 1.1 (0.4-3.4) Selection: referral for index test 0.5 (0.3-0.9) Selection: other test results 0.9 (0.6-1.3) Limited challenge 0.9 (0.6-1.3) Increased challenge 1.0 (0.6-1.7) Nonconsecutive sample 1.5 (1.0-2.1) Random sample 1.7 (0.9-3.2) Sampling not reported 0.9 (0.6-1.3) Retrospective data collection 1.6 (1.1-2.2) Data collection not reported 1.0 (0.7-1.5) Post hoc definition of cutoff 1.3 (0.8-1.9) Cutoff definition not reported 0.9 (0.7-1.3) 5 2 3 0 **RDOR**

Assessment of items

- All items scored as yes/no/unclear
- Items phrased so that yes indicates absence of bias
- Background document describes how items should be scored

Practical Issues

- Number of assessors
- Background of assessors
- Resolving disagreement
- Piloting the assessment process
- Develop your quality assessment tool

Your quality assessment tool

- o Items to include
 - Core items
 - Additional items
 - select from suggested items
 - add your own if other items are important for your review topic
- Produce scoring guidelines specific to your review


Additional items

| 12. | If a cut-off value has been used, was it established before the study was started (prespecified cut-off value)? | | |
|-----|---|--|--|
| 13. | Is the technology of the index test likely to have changed since the study was carried out? | | |
| 14. | Did the study provide a clear definition of what was considered to be a "positive" result? | | |
| 15. | Was treatment started after the index test was carried out but before the reference standard was performed? | | |
| 16. | Was treatment started after the reference standard was carried out but before the index test was performed? | | |
| 17. | Were data on observer variation reported? | | |
| 18. | Were data on instrument variation reported? | | |
| 19. | Were data presented for appropriate patient sub-groups? | | |
| 20. | Was an appropriate sample size included? | | |
| 21. | Were objectives pre-specified? | | |

Presenting study quality

- Present the results of the quality assessment:
 - Graphically


Methodological Quality Graph



Review authors' judgments about each methodological quality item presented as percentages across all included studies.

Incorporating study quality

- Present the results of the quality assessment:
 - In a table
 - Graphically



Methodological quality summary.

Review authors' judgments about each methodological quality item for each included study.

Using study quality

- Present the results of the quality assessment:
 - In a table
 - Graphically
- Investigate individual quality items as potential sources of heterogeneity
- Basis for recommendations for future research

Formal incorporation of study quality

- Restricting the analysis to high quality studies
- Stratified analysis according to presence/absence of specific quality criteria
- Sensitivity analyses to investigate robustness of results
- Investigate several features simultaneously using meta-regression analysis

Always: define methodological criteria a priori

Problems with quality assessment

- Not as straightforward as it might sound!
- Hampered by poor reporting
- Quality assessment is subjective
- Quality scores are <u>not</u> recommended
- Statistical incorporation of quality problematic with limited studies

Now it's your turn!

Example: BNP for heart failure


- Aim: To assess the accuracy of BNP for the diagnosis of heart failure
- In small groups:
 - Produce a flow diagram for the study
 - Discuss (attention to what has been done, what is missing and possible consequences):
 - QUADAS item 1 (spectrum)
 QUADAS items 2, 4 and 5 (verification)
 - Discuss the conclusion of the authors

QUADAS items

| 1 | Was the spectrum of patients representative of the patients who will receive the test in practice? | | |
|----|---|--|--|
| 2 | Is the reference standard likely to correctly classify the target condition? | | |
| 3 | Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests? | | |
| 4 | Did the whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis? | | |
| 5 | Did patients receive the same reference standard regardless of the index test result? | | |
| 6 | Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard)? | | |
| 7 | Were the index test results interpreted without knowledge of the results of the reference standard? | | |
| 8 | Were the reference standard results interpreted without knowledge of the results of the index test? | | |
| 9 | Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? | | |
| 10 | Were uninterpretable/ intermediate test results reported? | | |
| 11 | Were withdrawals from the study explained? | | |

Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ 2000;320.9906-8

Flowchart



Conclusions

- Quality assessment is essential, but exact effects not (yet) known
- The QUADAS tool should be used as a starting point
- Study quality should be incorporated into all reviews
- The quality items and scoring guidelines should be tailored to your review question
- The results of the quality assessment should be presented
- No quality scores and cut-offs for 'good' quality